Warner Chilcott and Paratek Pharmaceuticals Sign Collaboration Agreement for Novel, Narrow-Spectrum Agents for Acne and Rosacea

FAJARDO, Puerto Rico and BOSTON, July 9 /PRNewswire/ --

Warner Chilcott Company, Inc. and Paratek Pharmaceuticals, Inc. announced
today that the two companies have entered into an exclusive license agreement
for the development and commercialization of novel, narrow-spectrum
tetracyclines for the treatment of acne and rosacea.

Tetracycline antibiotics are the leading approved systemic treatments of
moderate to severe inflammatory acne. Discovered decades ago as
broad-spectrum systemic antibiotics, tetracyclines have been shown to be
potent anti-acne agents. Paratek has utilized its expertise in chemistry to
develop novel narrow-spectrum antibacterial tetracyclines with improved
anti-inflammatory activity, tolerability and other properties for the next
generation treatment of acne and rosacea. These compounds represent the first
tetracycline-derived new molecular entities ever to be synthesized
specifically as improved therapeutics for dermatologic diseases.

"We look forward to a productive collaboration with Paratek as we work
together to progress Paratek's novel tetracycline products through the
development process and into commercialization," said Roger Boissonneault,
Chief Executive Officer and President of Warner Chilcott.

"We are pleased to announce our collaboration with Warner Chilcott, a
proven leader in the development and commercialization of dermatology
products," said Stuart B. Levy, M.D., Co-founder and Chief Scientific Officer
of Paratek Pharmaceuticals. "For years, dermatologists have sought therapies
with a more targeted spectrum of activity. While effective, currently
marketed tetracyclines possess antibacterial activity against a broad number
of organisms not associated with acne or rosacea, which can lead to adverse
consequences such as resistance development among life-threatening bacteria
and persistent side effects. Paratek's proprietary compounds have been
designed to circumvent these issues by better targeting the causative
bacteria and retaining potent anti-inflammatory properties."

Under the terms of the agreement, Warner Chilcott will assume
responsibility for clinical development of the tetracycline derivative
products and will have exclusive rights to market the products in the United
States. Paratek received an up-front payment and will be eligible to receive
additional payments upon achievement of certain development and regulatory
approval milestones. Warner Chilcott will pay a royalty to Paratek on sales
of any product under the agreement.

The leading candidate under the agreement is in preclinical development
and expected to enter clinical development in 2008.

Warner Chilcott Company Inc. is a subsidiary of Warner Chilcott Limited
(Nasdaq: WCRX).

About Warner Chilcott

Warner Chilcott is a specialty pharmaceutical company focused on
developing, manufacturing, marketing and selling branded prescription
pharmaceutical products in women's healthcare and dermatology in the United
States. (WCRX-G)

Read more on www.warnerchilcott.com.

About Paratek Pharmaceuticals

Paratek Pharmaceuticals, Inc. is engaged in the discovery and
commercialization of new therapeutics that treat serious and life-threatening
diseases, with a particular focus on the growing worldwide problem of
antibiotic resistance. Paratek is advancing novel compounds that can
circumvent or block bacterial resistance involving technology initially
developed by Paratek co-founder Dr. Stuart Levy's laboratory at Tufts
University School of Medicine, and licensed by Paratek. In addition to its
tetracycline-derived antibacterials, Paratek is developing small molecule
drugs that can prevent infection by interfering with Multiple Adaptational
Response (MAR) mechanisms in bacteria.

Outside the antibacterial therapeutic area, Paratek has also established
an effort to exploit its novel tetracycline derivatives and their unique
mechanism of action in selected anti-inflammatory and neurodegenerative
conditions. Paratek has an active chemical synthesis effort to produce novel
and diverse small molecules, with the goal of developing non-antibacterial
compounds with improved activity in serious inflammatory and
neurodegenerative diseases based upon a growing body of clinical and basic
research supporting this approach.

Paratek is privately held and headquartered in Boston, Massachusetts,
USA. For more information, visit Paratek's website at
http://www.paratekpharm.com/.

Warner Chilcott's Forward-Looking Statements

This press release contains forward-looking statements, including
statements concerning our product development efforts. These statements
constitute forward-looking statements within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities Exchange Act of
1934. The words "may," "might," "will," "should," "estimate," "project,"
"plan," "anticipate," "expect," "intend," "outlook," "believe" and other
similar expressions are intended to identify forward-looking statements.
Readers are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of their dates. These forward-looking
statements are based on estimates and assumptions by our management that,
although we believe to be reasonable, are inherently uncertain and subject to
a number of risks and uncertainties.

The following represent some, but not necessarily all, of the factors
that could cause actual results to differ from historical results or those
anticipated or predicted by our forward-looking statements: our substantial,
indebtedness; competitive factors in the industry in which we operate; our
ability to protect our intellectual property; a delay in qualifying our
manufacturing facility to produce our products or production or regulatory
problems with either third party manufacturers upon whom we rely for some of
our products or our own manufacturing facility; pricing pressures from
reimbursement policies of private managed care organizations and other third
party payors, government sponsored health systems, the continued
consolidation of the distribution network through which we sell our products,
including wholesale drug distributors and the growth of large retail drug
store chains; the loss of key senior management or scientific staff; an
increase in litigation, including product liability claims and patent
litigation; government regulation affecting the development, manufacture,
marketing and sale of pharmaceutical products, including our ability and the
ability of companies with whom we do business to obtain necessary regulatory
approvals; our ability to successfully complete the implementation of a
company-wide enterprise resource planning system without disrupting our
business; our ability to manage the growth of our business by successfully
identifying, developing, acquiring or licensing and marketing new products,
obtain regulatory approval and customer acceptance of those products, and
continued customer acceptance of our existing products; and other risks
detailed in our annual report for 2006 filed with the Securities and Exchange
Commission on Form 10-K and from time-to-time in our financial statements and
other investor communications.

We caution you that the foregoing list of important factors is not
exclusive. In addition, in light of these risks and uncertainties, the
matters referred to in our forward-looking statements may not occur. We
undertake no obligation to publicly update or revise any forward-looking
statement as a result of new information, future events or otherwise, except
as may be required by law.

Web site: http://www.warnerchilcott.com
              http://www.paratekpharm.com